V
Vamsidhar Velcheti
Researcher at New York University
Publications - 251
Citations - 11179
Vamsidhar Velcheti is an academic researcher from New York University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 42, co-authored 194 publications receiving 6799 citations. Previous affiliations of Vamsidhar Velcheti include Yale University & Case Western Reserve University.
Papers
More filters
Journal ArticleDOI
Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology
Kaustav Bera,Kurt A. Schalper,David L. Rimm,Vamsidhar Velcheti,Anant Madabhushi,Anant Madabhushi +5 more
TL;DR: A broad framework is provided for incorporating AI and machine learning tools into clinical oncology, with an emphasis on biomarker development, and some of the challenges relating to the use of AI are discussed, including the need for well-curated validation datasets, regulatory approval and fair reimbursement strategies.
Journal ArticleDOI
Programmed death ligand-1 expression in non-small cell lung cancer.
Vamsidhar Velcheti,Kurt A. Schalper,Daniel Carvajal,Valsamo Anagnostou,Konstantinos N. Syrigos,Mario Sznol,Roy S. Herbst,Scott N. Gettinger,Lieping Chen,David L. Rimm +9 more
TL;DR: Multivariate analysis showed that PD-L1 expression was significantly associated with better outcome independent of histology and further studies are required to determine the value of this marker in prognosis and prediction of response to treatments targeting this pathway.
Journal ArticleDOI
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
Joseph McLaughlin,Gang Han,Kurt A. Schalper,Daniel E. Carvajal-Hausdorf,Vasiliki Pelekanou,Jamaal Rehman,Vamsidhar Velcheti,Roy S. Herbst,Patricia LoRusso,David L. Rimm +9 more
TL;DR: Objective determination of PD-L1 protein levels in NSCLC reveals heterogeneity within tumors and prominent interassay variability or discordance, due to different antibody affinities, limited specificity, or distinct target epitopes.
Journal ArticleDOI
Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Ferdinandos Skoulidis,Bob T. Li,Grace K. Dy,Timothy J. Price,Gerald Steven Falchook,Jürgen Wolf,Antoine Italiano,Martin Schuler,Martin Schuler,Hossein Borghaei,Fabrice Barlesi,Terufumi Kato,Alessandra Curioni-Fontecedro,Adrian G. Sacher,Alexander I. Spira,Suresh S. Ramalingam,Toshiaki Takahashi,Benjamin Besse,Abraham Anderson,Agnes Ang,Qui Tran,Omar Mather,H. Henary,Gataree Ngarmchamnanrith,Gregory Friberg,Vamsidhar Velcheti,Ramaswamy Govindan +26 more
TL;DR: Sotorasib showed anticancer activity in patients with KRAS p.G12C-mutated advanced solid tumors in a phase 1 study as discussed by the authors, and particularly promising anti-cancer activity was observed i...
Journal ArticleDOI
In situ Tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
Kurt A. Schalper,Vamsidhar Velcheti,Daniel Carvajal,Hallie Wimberly,Jason R. Brown,Lajos Pusztai,David L. Rimm +6 more
TL;DR: PD-L1 mRNA expression is identified in nearly 60% of breast tumors and it is associated with increased TILs and improved recurrence-free survival, which support the evaluation of PD-1/PD- L1–targeted therapies in breast cancer.